Neuroprotective Effect of Sonic Hedgehog Mediated PI3K/AKT Pathway in Amyotrophic Lateral Sclerosis Model Mice

Yan Qi1,2 · Chen Yang1 · Hui Zhao2 · Zhanjin Deng1 · Jin Xu2 · Weijing Liang2 · Zhitang Sun1 · John Dirk Vestergaard Nieland3

Received: 14 February 2022 / Accepted: 16 August 2022 / Published online: 3 September 2022
© The Author(s) 2022

Abstract
The Sonic Hedgehog (SHH) signaling pathway is related to the progression of various tumors and nervous system diseases. Still, its specific role in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), remains studied. This research investigates the role of SHH and PI3K/AKT signaling pathway proteins on ALS development in a SOD1-G93A transgenic mouse model. After injection of SHH and PI3K/AKT signaling pathway inhibitors or agonists in hSOD1-G93A (9 weeks of age) transgenic mice, we studied skeletal muscle pathology using immunohistochemical staining and Western blot methods. In addition, recorded data on rotation time, weight, and survival were analyzed for these mice. Our study showed that the expression of SHH, Gli-1 and p-AKT in ALS mice decreased with the progression of the disease. The expression of p-AKT changed together with Gli-1 while injecting PI3K/AKT signaling pathway inhibitor or agonist; SHH and Gli-1 protein expression remained unchanged; p-AKT protein expression significantly decreased while injecting PI3K/AKT signaling pathway inhibitor. These results indicate that SHH has a regulatory effect on PI3K/AKT signaling pathway. In behavioral experiments, we found that the survival time of hSOD1-G93A mice was prolonged by injection of SHH agonist while shortened by injection of SHH inhibitor. In conclusion, we confirmed that the SHH pathway played a neuroprotective role in ALS by mediating PI3K/AKT signaling pathway.

Keywords ALS · PI3K/AKT signaling pathway · SHH · Gli-1 · SOD1-G93A

Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. It is the most common motor neuron disease. The patient eventually dies because of the loss of the upper and lower motor neurons that control voluntary movement. Moreover, the average course of the disease is only 3–5 years. So far, there is no effective treatment for ALS [1]. The disease is a complex disease caused by multiple factors and genes. These pathogenic theories have been more widely accepted: glutamate excitotoxicity, oxidative stress, protein misfolding, mitochondrial changes, axon transport disorders, neuroinflammation, exogenous toxins, virus infection, gene mutation, abnormal RNA metabolism, and lipid metabolism [2–7]. The superoxide dismutase 1 (SOD1) gene is one of the main pathogenic genes of ALS. Since SOD1 mutation was found, more than 30 genes are associated with familial Amyotrophic Lateral Sclerosis (fALS). Among these genes, five (C9ORF72, SOD1, TARDBP, FUS, TBK1) had the highest mutation frequency in fALS, which were 40%, 20%, 5%, <5% and <5% respectively [8]. Abnormal expression of SOD1 can produce toxicity, cause oxidative stress damage, and affect the structure and function of normal neurons [9].

Lee et al. found the hedgehog (HH) gene for the first time in the study of wingless mutation in Drosophila [10]. The HH family of spinal animals is divided into three subgroups, namely Desert Hedgehog (DHH), India hedgehog (IHH),
and Sonic Hedgehog (SHH). SHH is widely expressed in human tissues [11]. The SHH signaling pathway mainly comprises the membrane receptors patched (Pth), smoothened (SMO), and the downstream transcription factors Gli family. The Gli family of transcription factors includes Gli1, Gli2, and Gli3 [12, 13]. In the presence of SHH, Gli1 plays a significant role in activating the pathway to be used as an indicator of the expression of this pathway [14]. The SHH signaling pathway is essential for vertebrate embryonic development, dynamic tissue balance, and regeneration [15]. It is an essential signaling pathway regarding the formation of the nervous system [16]. Studies have shown that the SHH pathway can play multiple protective effects on acute brain injury, long-term memory impairment, and synaptic damage [17]. The imbalance of SHH gene expression may restrict the development and growth of the forebrain and hypothalamus ventral midline and even result in craniofacial deformity [18]. Studies have shown that SHH gene expression can improve cell survival by increasing cell proliferation and promoting the G1 cell cycle [19]. SHH signal transduction is crucial to regulating apoptosis [20]. At the same time, the activation of the SHH signaling pathway is related to the progress of various tumors [21] and nervous system diseases [22].

In recent years, studies have found that PI3K/AKT signaling pathway is involved in ALS disease, and neuroprotective drugs can exert a protective role through this pathway. For example, butylphthalide can activate PI3K/AKT/GSK-3β signal pathway in the ischemic cerebral infarction model, thereby reducing nerve function damage and protecting local nerve cells [23]. Improving mitochondrial dysfunction [24], inhibiting apoptosis, and reducing oxidative stress have been considered therapeutic strategies for ALS [25]. Many studies have shown that PI3K/AKT pathway can be activated to increase anti-apoptotic protein expression levels and reduce pro-apoptotic protein expression levels to improve cell survival rate and mitochondrial function in ALS. For example, Xiang Yin [26] and other studies have found that astrocyte elevation gene-1 (AEG-1) (AEG-1) can regulate PI3K/AKT pathway. The lack of AEG-1 in ALS motor neurons leads to inhibition of the PI3K/AKT pathway and an increase in cell apoptosis. However, activation of the PI3K/AKT signaling pathway can protect the cerebral cortex and astrocytes [27] from the damage due to oxidative stress. Zhao et al. [28] found that SHH and PI3K/AKT signaling pathways are closely related to Neuro-2a cells apoptosis.

Based on the above studies, we selected the SOD1-G93A transgenic mouse model of ALS, and the study aimed to clarify the connection between SHH and PI3K/AKT signaling pathway and its role in ALS. To confirm that activation of the SHH signaling pathway can play a neuroprotective role by mediating the PI3K/AKT signaling pathway, we administered agonists and inhibitors of different signaling pathways. We analyzed disease phenotypes, muscle pathology, and behavioral manifestations in mice. This study provides a theoretical basis for the SHH pathway to be an effective target in ALS treatment.

Materials and Methods

Animals

Transgenic mice (C57B6.CgTg SOD1-G93A-1Gur/J) were originally from the Jackson Laboratory and later supplied by Professor Honglin Feng, Harbin Medical University, China. Stable breeding was maintained by mating purchased heterozygous SOD1-G93A male mice with C57BL/6 J female mice. The mice were kept in a temperature-controlled (22–24°C) room with a 12 h light and 12 h dark cycle providing clean drinking water and granular mouse feed, four per cage with a male and female ratio of 1:3. All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Shanxi Medical University (DW2022031).

hSOD1G93A-positive and age-matched negative mice were euthanized. The selected mice were anesthetized and perfused transcardially with phosphate-buffered saline (PBS, pH = 7.4) for 10 min, then 4% paraformaldehyde (PFA) in 0.1% PBS for 1 h. The spinal cord was dissected, post-fixed with 4% PFA for 48 h and then paraffin-embedded. A series of spinal cord sections were made and sectioned at a thickness of 5 μm. Muscle tissue was quickly removed from mouse gastrocnemius, then placed in liquid nitrogen and stored in a refrigerator.

QRT-PCR

In this study, to minimize the used number and reduce the pain of animals, mice carrying SOD1G93A mutations were identified by PCR amplification of the DNA extracted from the tails using protocols provided by Jackson Lab. The primers used were 5’-CTAGGCCCACAGAATCGATC-3’ and 5’-GAGTGGAATCGATCCATC-3’ for IL-2; 5’-CATCAGCCCTAATCCATCTG-3’ and 5’-CGCGAC TAAACAATCAAGTG-3’ for hSOD1. The mics DNA was extracted and added to the prepared PCR amplification system. We performed PCR using the SYBR® Green PCR Master Mix (Life Tech) on an ABI 7300 (Applied Biosystems, Foster City, CA, USA) with the following program: 95°C for 5 min, once in total; 95°C for 45 s, 58°C for the 30 s, 72°C for 30 s, 35 reaction cycles; 72°C for 5 min, once in total; 4°C for preservation. After electrophoresis, the gel
was taken into the Imaging System (Bio-Rad, USA) and observed, photographed, and analyzed.

**Groups and Drug Treatments**

Accumulating evidences [29–33] demonstrated that female mice show less variability in the survival time than male mice, and the instability of the males’ endocrine hormones would affect the experimental results [34–36]. Therefore consistent with previous reports, female mice were elected in this study. Well-identified ALS females (9 weeks of age) were selected into ALS, ALS+PUR, ALS+CYC, ALS+LY, and WT littermates as a control group with ten experimental animals in each group. Wild-type (WT) SOD1 mice are negative littermates of the G93A-SOD1 mice in the same nest. Drugs were injected every three days from early-onset (9 weeks of age) until the behavioral end-stage of mice and finally removed spinal cord tissue after euthanasia. If the mice died unexpectedly during the experiment, the corresponding mouse-age mice were added as described above.

Purmorphamine (PUR) (15 mg/kg) activates SHH signaling pathway by binding and activating the SMO protein [12, 13, 37, 38]. Cyclopamine (CYC) (12 mg/kg) [39, 40] is an inhibitor of the SHH signaling pathway. LY294002 (10 mg/kg) [41] can inhibit the activation of the PI3K/Akt signaling pathway.

We dissolved the reagent in dimethyl sulfoxide (DMSO) and then diluted the mixture with pure water to 10 mg/mL (DMSO concentration of 5%). PUR (15 mg/kg), CYC (12 mg/kg), or LY294002 (10 mg/kg) was injected intraperitoneally. The control groups simultaneously received the intraperitoneal injection of the same equivalent solvent (5% DMSO concentration).

**Western Blotting**

Fresh lumbar spinal cord tissue was extracted and put into RIPA lysate (AR0102-100, Boster), adding protease inhibitor PMSF (AR1178, Boster) and phosphatase inhibitor (AR1183, Boster). BCA protein concentration assay kit (AR0146, Boster) was used to determine the protein concentration.

The total proteins from the spinal cord were separated by electrophoresis using 10% SDS–polyacrylamide gel, then transferred onto PVDF membranes. The membranes were blocked with 5% non-fat milk for 2 h at room temperature, then incubated overnight at 4 °C with the following antibodies: Rabbit Anti-SHH Polyclonal Antibody (bs-1544R, Bioss), Rabbit Anti-Gli-1 Polyclonal Antibody (bs-1206R, Bioss), Phospho-AKT (Ser473, Cell Signaling Technology), AKT polyclonal antibody (AP0095, Bioworld) or β-actin (AP0060, Bioworld) antibodies. After washing, the membranes were incubated with Goat anti-Rabbit IgG (BA1054, Boster) for 1 h at room temperature. The blots were visualized by the chemiluminescence-based detection kit (ECL Kit, Boster). Densitometry analysis was performed with a System Gel Doc XR + IMAGE LAB (Bio-Rad, USA) and quantified with NIH Image software (Image J).

**Immunohistochemistry**

To quantify the number of motor neurons, every 10th section was selected, with a total of 30 sections being collected for each animal. The horizontal sections of the mouse lumbar spinal cord were sectioned at a thickness of 5 μm. After gradient dewaxing and dehydration, all sections were subsequently rinsed three times with 0.1 M PBS and blocked in BSA of 5% for 20 min, then incubated 1 h at 4°C with the following primary antibodies, anti-SHH, anti-Gli1, Phospho-AKT. Then the sections were incubated 30 min at 37°C with Goat anti-Rabbit IgG and subsequently rinsed three times with 0.1 M PBS. SABC was added and incubated at 37°C for 30 min, then rinsed. The specimens that developed color at room temperature with DAB were examined under a microscope. The samples were stained with Hematoxylin and finally sealed with resin. The expression of SHH, Gli1 and p-AKT cells in the cervical spinal cord was evaluated by Image J.

**Pathological Analysis of the Gastrocnemius Muscle**

Fresh gastrocnemius was dissected and processed by liquid nitrogen freezing at a – 20°C cryostat Section (10 μm). And it was stained by hematoxylin and eosin (H&E), nicotinamide adenine dinucleotide hydrogen tetrazolium reductase (NADH-TR), Oil red O, PAS staining, or Modified Gomori Trichrome (MGT). They were observed and photographed with a microscope (Motic VM). We calculate at the same magnification.

H&E: hematoxylin–eosin staining kit (C0105M, Beyotime); NADH-TR: NADH (ST358, Beyotime); Oil red O: Oil red O staining kit (C0157M, Beyotime); PAS staining: periodate Schiff staining (PAS) kit (C0142M, Beyotime); MGT: made by myself with phosphotungstic acid (0.6 g), glacial acetic acid (1.0 ml), solid green (0.3 g), chromotropic acid 2R (0.6 g), Distillation-Distillation water to 100 ml.

**Assessment of Mouse Motor Ability, Body Weight, and Survival**

The dyskinesia of mice was evaluated by the 4-point scoring system [42]:

- 4 points for no signs of dyskinesia
- 3 points for noticeable shaking of hind limbs
- 2 points for abnormal gait
- 1 point for dragging at least one hind limb
- 0 point for cannot turn over in 30 s (0 point represents the end stage of the disease)

We calculated the survival rate of mice in different groups and recorded the survival time of mice. The body-weight of mice was measured and recorded once a week from the initial stage of onset (9 weeks old) until the end of the mice. The criteria of an early stage of mice include lifting the tail of mice, hind limb tremor, and (or) limb weakness. The criteria of late-stage: the mice were placed in supine or lateral position (bilateral) and could not turn over within 30 s.

Rotarod test was performed from 63 days of age once a week to evaluate the motor ability of ALS mice. Mice were trained at 8 rpm for a week before performing a formal Rotarod Test. We recorded the time of the mice on the rotating rod instrument with a diameter of 3 cm (16 rpm). The maximum recorded value is 180 s, but it is recorded as the actual time when it is lower than 180 s.

**Statistical Analysis**

We designed graphs with Graph Pad Prism 8. Data were displayed as mean ± standard deviation. Statistical analysis was carried out with a t-test and one-way ANOVA. Repeated measurement data ANOVA was adopted to analyze the body weight and rotation time data. Moreover, the Kaplan Meier life test performed the probability of survival. Differences were statistically significant at $P < 0.05$.

**Results**

**SHH and PI3K/AKT Pathways are Involved in the Development of ALS Disease**

The SOD1 G93A female (ALS) and female WT mice in the same cage were carefully fed and closely observed for 9 weeks. At this time, ALS mice had shown progressive impairment of early motor function. We killed untreated mice at 9, 13, and 17 weeks of age, taking tissue samples.

There was no significant difference in SHH protein expression between ALS and WT mice at 9 weeks of age, as shown in Fig. 1a. However, at 13 and 17 weeks of age, the expression of SHH decreased with the age of ALS mice ($P < 0.05$) (Fig. 1b). At the same time, the expression of transcription factor Gli-1 downstream of the SHH pathway was also downregulated ($P < 0.05$) (Fig. 1c). With the progression of ALS disease, p-Akt protein expression also statistically significantly decreased ($P < 0.05$) (Fig. 1d). Through immunohistochemical staining, we observed that the motor neuron cells in the lumbar enlargement of the spinal cord increased express Gli1 in the anterior horn of gray matter compared to the posterior horn, posterior cord, and lateral cord of gray matter (Fig. 2a). In the spinal cord of WT mice, evenly distributed motor neuron cells with normal morphology were observed in the horizontal section of the spinal
Compared with WT mice, the overall number of motor neuron cells in the spinal cord of ALS mice decreased, and the motor neuron cells expressing Gli-1 (Fig. 2b) and p-AKT (Fig. 2d) in the anterior horn gradually reduced with the progression of the disease ($P < 0.01$).

**SHH Participates in the Development of ALS by Mediating PI3K/AKT Pathway**

Female ALS mice with the apparent onset of disease (9 weeks old) were treated with different medicine, and the expression of Gli-1, SHH, and PI3K/AKT proteins was measured in Fig. 3a. Compared to WT mice, SHH, Gli-1, and p-AKT protein in the ALS group decreased; however, treatment with the PUR group improved these proteins' expression significantly. CYC-treated ALS mice considerably reduced SHH, Gli-1, and p-AKT proteins expression. There was no significant difference in SHH protein expression between ALS and ALS + LY mice ($P < 0.05$) (Fig. 3b). In addition, as can be seen in Fig. 3c, the expression of Gli-1 between ALS and ALS + LY mice were also the same. However, the expression of the p-AKT protein (Fig. 3d) in ALS + CYC and ALS + LY mice decreased statistically significantly compared to other groups ($P < 0.05$). The expression of Gli-1 protein and p-AKT protein in the lumbar spinal cord of ALS mice was detected by immunohistochemistry, and we counted the number of motor neuron cells under the microscope (Fig. 4a). Compared to the ALS mice (Fig. 4b), the numbers of Gli-1 cells increased in ALS + PUR mice while decreasing significantly in ALS + CYC mice;
Fig. 3 The expression of SHH and PI3K/AKT pathway related proteins (a). The expression of SHH, Gli1 and p-AKT (b, c, d) in ALS group, ALS + PUR group, ALS + CYC group and ALS + LY group. (N = 10, *: vs ALS group, #: vs ALS + PUR group, &: vs ALS + CYC group. */#/&: p < 0.05, **/###/#&: p < 0.01, ###/###: p < 0.001)

Fig. 4 Immunohistochemical staining of horizontal sections of anterior horn of lumbar spinal cord in mice. Gli-1, p-AKT (a) moto neuron cells in the anterior horn area and the number of moto neuron cells (b, c), abnormal moto neuron cells (indicated by the arrow) can be seen. The difference between the groups of markers was statistically significant. (N = 10, #: vs WT group, #: vs ALS group. **: P < 0.01, ****/####: P < 0.001. Scale bar of all pictures: 100 μm)
meanwhile, p-AKT cells behaved the same as Gli-1 cells in ALS + PUR mice as well as in ALS + CYC mice (Fig. 4c). Moreover, p-AKT cells in ALS + LY mice decreased significantly, while the number of Gli-1 cells in ALS + LY mice remained unchanged (P < 0.05) (Fig. 4b and c).

**PUR Prolonged the Survival Time of ALS Mice and Delayed the Development of ALS**

Female ALS mice were randomly divided into ALS group, ALS + PUR group, and ALS + CYC group, with 10 experimental mice in each group. In previous experiments, we found that the SHH and the Gli-1 (downstream protein) expression decreased significantly in the lumbar spinal cord of ALS mice. Therefore, we used the receptor agonist PUR or antagonist CYC to intervene in the SHH pathway and observe its effects on mice's body weight and survival rate.

Compared with the mice in the ALS group, the weight of ALS + PUR group mice did not change significantly (P = 0.396, Fig. 5a), but the survival rate (P = 0.003, Fig. 5b) increased significantly, and the survival time prolonged. The weight of ALS + CYC group mice decreased. There was no statistical significance (P = 0.069). However, the survival time decreased significantly (P = 0.002). The rod rotation time of ALS mice gradually shortened from 9 weeks. The latency to fall of ALS + PUR group was declining slower than the ALS group, indicating PUR could delay the damage of motor function of ALS transgenic mice (P = 0.022) (Fig. 5c). The latency to fall of the CYC-treated mice was significantly shortened compared to ALS and ALS + PUR treated mice (P < 0.001).

**PUR Delays Muscle Morphological Damage in SOD1-G93A Mice**

Muscle atrophy is one of the main manifestations of ALS disease. We analyzed the morphological changes of the gastrocnemius muscle in order to confirm the beneficial effect of PUR on muscle tissue of ALS disease mice. We performed a histochemical analysis with H&E, MGT, NADH-TR, oil red O, and PAS staining. Compared to the WT animals, H&E staining showed that ALS disease animals had abnormal manifestations such as muscle cell atrophy and nuclear aggregation. The deterioration of muscle tissue was more severe in ALS + CYC and ALS + LY group animals, whereas herein the ALS + PUR animals, the deterioration was alleviated (Fig. 6a). The MGT staining can demonstrate ragged red fibers and intermyofibrillar red deposits. In normal cells (WT control group), the muscle fibers were dark green, and the nucleus and peripheral nerve myelin sheath were purplish-red (Fig. 6b).

Stained and broken red fibers can be observed under the sarcolemma in the ALS group, mainly composed of abnormally increased mitochondria. NADH-TR staining was located in mitochondria and sarcoplasmic reticulum. We used this method to observe the abnormal distribution of muscle fibers and myofibrillar reticulum (Fig. 6c). In the WT group, the normal types of muscle fibers: type I muscle fibers were dark blue, and type II muscle fibers were
light blue and distributed in a mosaic shape. Due to sarcoplasmic condensation, deep staining in severely atrophic muscle fibers can also occur in NADH-TR staining. The number of atrophic cells stained with dark blue in the ALS group was more than that of the WT group. In addition, muscle fiber fragmentation occurred in the ALS + CYC group and ALS + LY group. The morphology deterioration of muscle fiber was reduced in the ALS + PUR group. Oil red O staining specifically shows neutral fat, which is deeply colored and can show smaller fat droplets (Fig. 6d). The results showed no noticeable abnormalities in each group, indicating no fat deposition (bright red or orange) in mice gastrocnemius muscle cells. The content and distribution of glycogen in cells can be observed with the PAS staining (Fig. 6e). In normal cells, type I muscle fibers are reddish, type II muscle fibers are purplish red, and the nucleus is blue. The abnormal myocyte in ALS mice showed glycogen loss. In ALS + CYC and ALS + LY mice, the glycogen loss was worse, and the glycogen was unevenly distributed in different muscle fibers.

**Discussion**

SHH signaling pathway is an important signal transduction pathway related to the development of the central nervous system, which plays a key role in the differentiation of precursor cells of neurons in the body [43–45]. The Shh signaling pathway is incompletely understood and interactions with other signaling pathways are possible [47]. SHH may maintain neural stem cells and promote the formation of oligodendrocytes (Yang [48]. Oxidative stress is one of the most important pathological mechanisms in neurodegenerative diseases. SHH promoted the
expression of the anti-apoptotic gene Bcl-2 and inhibited expression of pro-apoptotic gene Bax. Activation of SHH signals upregulated both Neurotrophic factors vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) [49]. SHH signaling pathway was involved in these diseases, but the underlying mechanisms remained elusive.

This study also found the damage to the SHH signal pathway in the spinal cord of ALS female mice and SHH expression by drug stimulation delayed the disease progression of spinal motor neurons in ALS mice. We observed the cell morphology, calculated the numbers of spinal cord tissue, and did Western blot proteins testing of different day-ages mice. The SHH, Gli-1, and p-AKT proteins expression were down-regulated in ALS mice, indicating that ALS mice’s SHH pathway and PI3K/AKT signaling pathway are affected.

Gli is SHH downstream signal molecule relating to the central nervous system. Up-regulation of Crabp1 by SHH is mediated by Gli1, which binds the Gli target sequence in Crabp1’s neuron-specific regulatory region upstream of minimal promoter [50]. Activation of PI3K/AKT pathway and SHH/Gli1 pathway is associated with glioma progression [51]. CPH was neuroprotective by restoring neurobehavioral alterations and significantly reducing the elevated PI3K, AKT, and mTOR protein levels, and modulating the apoptotic markers in rat brain homogenate [52]. SHH can increase the activity of the PI3K/AKT pathway, inhibit the activity of GSK3, and then inhibit the degradation of Gli protein by the ubiquitin–proteasome system (Kanda [53]). This study also found that activating SHH signaling by intraperitoneal injection of PUR can improve the disease symptoms and prolong the life of ALS model mice. The results showed that activating the SHH signaling pathway with PUR increased the Gli-1 expression and could thereby overcome the inhibition of p-AKT protein. When CYC inhibited the SHH signaling pathway, the p-AKT protein expression was reduced, resulting in a deterioration of the ALS symptoms. In the behavioral test, the results also showed that PUR injection could improve the motor function of mice, while CYC injection worsened the motor function of mice. These results suggest that Akt is a downstream molecule of SHH, and activation of PI3K/Akt pathway may be necessary for the protective effect of SHH on motor neurons.

To confirm the relation between PI3K/AKT signaling pathway and SHH expression. We used an intraperitoneal injection of the PI3K/AKT inhibitor LY294002 [41, 54]. The results showed that the expression of p-AKT in the PI3K/AKT signaling pathway was inhibited. However, the expression of Gil-1 was not affected, suggesting that SHH-mediated Gil-1 expression was independent of PI3K activity. The neuroprotective effect of SHH disappeared when PI3K/AKT signaling pathway was inhibited. Blocking PI3K/Akt pathway more significantly inhibited motor neuron cell viability than blocking SHH. The results further demonstrated that the protective effect of SHH on motor neurons is realized through the activation of the PI3K/Akt pathway, which is necessary for SHH to reduce apoptosis and improve cell survival.

Both the MAPK/ERK and PI3K/Akt pathways are regulated by Shh and are required for its effects on adult myoblasts. However, The PI3K/Akt pathway mediates and is essential for Shh-stimulated muscle cell differentiation and is essential for this process, whereas MAPK/ERK is less important [55]. In this study, H&E staining showed that ALS animals had obvious abnormal manifestations in muscle tissue, such as muscle cell atrophy and nuclear aggregation. The deterioration of these morphologies was more serious in ALS+CYC and ALS+LY animals. However, the deterioration was alleviated in ALS+PUR animals. MGT staining showed that the number of atrophic cells stained with dark blue in ALS animals increased. In addition, muscle fiber fragmentation occurred in ALS+CYC and ALS+LY animals. While the deterioration of muscle fiber morphology was more reduced in ALS+PUR animals, Oil red O staining was adopted to observe the fat deposition (bright red or orange) in mouse gastrocnemius muscle cells. The results showed no abnormality in each group; PAS staining showed glycogen loss in the abnormal myocyte in ALS animals and improved lesions in ALS+PUR animals, but there was no statistical significance. The glycogen loss of ALS+CYC and ALS+LY animals was worse than that of other groups, and glycogen was unevenly distributed in different muscle fibers. The results of the cell, tissue, and behavioral studies all showed that SHH could regulate the PI3K/AKT signaling pathway, and the disturbance of the regulation leads to disease worsening.

In this study, the SHH signaling pathway in SOD1 mutation-induced ALS was analyzed and shown to play a prominent role in neuronal degeneration in ALS. SHH signaling pathway can regulate ALS disease by mediating PI3K/AKT signaling pathway, and interfering with this pathway can significantly alleviate the progression of ALS disease. This study thereby provides a potentially effective target for the treatment of ALS disease and provides primary theoretical data for further studying the molecular mechanism of motor neuron degeneration.

**Conclusion**

SHH and PI3K/AKT signaling pathways inhibited in SOD1-G93A female mice.
The activation of the SHH signaling pathway can interfere with the expression of the PI3K/AKT signaling pathway. The activation of the SHH-PI3K/AKT signaling pathway can protect motor neuron cells and improve motor function, thereby prolonging the life of mice suffering from ALS.

Acknowledgements We appreciate all members of Shanxi Key Laboratory of Bone and Soft Tissue Injury Repair for their helpful technical support and constructive discussions.

Author Contributions Yan Qi and Chen Yang have equally contributed to the manuscript. Yan Qi and Chen Yang conducted the experiments. Yan Qi, Chen Yang and Jin Xu collected and analyzed the data. John Dirk Vestergaard Nielsen, Zhitang Sun, Chen Yang and Yan Qi drafted and revised the manuscript. Zhanjin Deng, Zhitang Sun, Weijing Liang and Hui Zhao conceived and designed the experiments. The final manuscript was read and approved by all authors.

Funding This work was supported by Shanxi Provincial Education Department Foundation (2019LO434) and Science and Technology Department of Shanxi Province Foundation (2019ID211500).

Data Availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of Interest All listed authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethics Approval All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Shanxi Medical University.

Consent to Participate All authors approved to participate.

Consent for Publication All authors approved publication.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Richards D, Morren John A, Pioro Erik P (2020) Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci 417:117054. https://doi.org/10.1016/j.jns.2020.117054

2. Mireia H-G, Gaja-Capdevila N, Vela JM et al (2020) Sigma 1 receptor as a therapeutic target for Amyotrophic Lateral Sclerosis. J Br J Pharmacol 178(6):1336–1352. https://doi.org/10.1111/bph.15224

3. Calió ML, Elisandra H, Amanda S et al (2020) Mitochondrial Dysfunction, Neurogenesis, and Epigenetics: Putative Implications for Amyotrophic Lateral Sclerosis Neurodegeneration and Treatment. J Front Neurosci 14:679. https://doi.org/10.3389/fnins.2020.00679

4. Project MinE ALS Sequencing Consortium (2018) CHCHD10 variants in amyotrophic lateral sclerosis: Where is the evidence? J Ann Neurol 84:110–116. https://doi.org/10.1002/ana.25273

5. Harrison JM, Rafuse VF (2020) Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1 mice. J Neurobiol Dis 145:105052. https://doi.org/10.1016/j.nbd.2020.105052

6. Trabjerg MS, Christian AD, Pam H et al (2021) Downregulating carnitine palmitoyl transferase 1 affects disease progression in the SOD1 G93A mouse model of ALS. J Commun Biol 4:509. https://doi.org/10.1038/s42003-021-02034-z

7. Qi Y, Xiang Y, Shuyu W et al (2016) PGC-1α Silencing Compounds the Perturbation of Mitochondrial Function Caused by Mutant SOD1 in Skeletal Muscle of ALS Mouse Model. J Front Aging Neurosci 8:37. https://doi.org/10.3389/fnagi.2015.00204. eCollection

8. Corcica P, Lumbroso S, Cazeneuve C et al (2020) Pre-symptomatic diagnosis in ALS. J Rev Neurol (Paris) 176:166–169. https://doi.org/10.1016/j.neurol.2019.07.027

9. Turner BJ, Kevin T (2008) Transgenics, toxicity and therapeutic in rodent models of mutant SOD1-mediated familial ALS. J Prog Neurobiol 85:94–134. https://doi.org/10.1016/j.pneurobio.2008.01.001

10. Lee JJ, von Kessler DP, Parks S, Beachy PA (1992) Secretion and localized transcript suggest a role in positional signaling for products of the segmentation gene hedgehog. J Cell Biol 119(1):33–50. https://doi.org/10.1083/jcb.119.1.33

11. Kramann R, Fleig Susanne V, Schneider Rebekka K et al (2015) Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J Clin Invest 125:2935–2951. https://doi.org/10.1172/JCI74929

12. Zhang H, Lanyan Hu, Minzhang C et al (2020) The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer. J Oncol Rep 44:2610–2620. https://doi.org/10.25273/jor.2020.7798

13. Zhang L, Yanjun Y, Zirui L et al (2020) Genetic and pharmacological activation of Hedgehog signaling inhibits osteoclastogenesis and attenuates titanium particle-induced osteolysis partly through suppressing the JNK/c-Fos-NFATc1 cascade. J Theranostics 10(15):6638–6660. https://doi.org/10.7150/jtheranostics.44793

14. Blaess S, Nora S, Roberta H-T et al (2014) Sonic hedgehog signaling in the development of the mouse hypothalamus. J Front Neuroanat 8:156. https://doi.org/10.3389/fnana.2014.00156

15. Kremer L, Elisabeth H, Alexandra B et al (2019) Discovery of the Hedgehog Pathway Inhibitor Pipindin that Targets P/IFiKIIIβ. J Angew Chem Int Ed 58:16617–16628. https://doi.org/10.1002/anie.201907632

16. Park S-R, Soo-Rim Kim, Hum Park Chan et al (2020) Sonic Hedgehog, a Novel Endogenous Damage Signal, Activates Multiple Beneficial Functions of Human Endometrial Stem Cells. J Mol Ther: the journal of the American Society of Gene Therapy 28(2):452–465. https://doi.org/10.1016/j.molther.2019.11.024

17. Liu D, Xuebei M, Weiwei Ma et al (2020) Purmorphamine Attenuates Neuro-Inflammation and Synaptic Impairments After Hypoxic-Ischemic Injury in Neonatal Mice via SHH Signaling. J Front Pharmacol 11:204. https://doi.org/10.3389/fphar.2020.00204
18. Sagai T, Takanori A, Akiteru M et al (2019) SHH signaling mediated by a prechordal and brain enhancer controls forebrain organization. J Proc Natl Acad Sci USA 116:23636–23642. https://doi.org/10.1073/pnas.1901732116

19. Chen Y, Zhu W (2019) Knockdown of the Sonic Hedgehog (SHH) Gene Inhibits Proliferation of Hep3B and SMCC-7721 Hepatocellular Carcinoma Cells via the PI3K/akt/pck1 Signaling Pathway. J Med Sci Monit: international medical journal of experimental and clinical research 25:6023–6033. https://doi.org/10.12659/JMM.914768

20. Kurosaka H, Trainor Paul A, Margot L-B, Angelo I (2015) Cranial nerve development requires co-ordinated SHH and canonical Wnt signaling. J Plos One 10(3):e0120821. https://doi.org/10.1371/journal.pone.0120821

21. Yuan Q et al (2015) AMP-activated protein kinase regulates sonic hedgehog pathway on oxygen glucose deprivation-induced neurotoxicity and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma. J Oncol Lett 4(20):52. https://doi.org/10.3892/ol.2016.11596

22. Wang C, Jie H, Xin L et al (2020) Isoflavonoids Attenuates Alzheimer’s Disease via Regulating Mitochondrial Function Through the PI3K/akt Pathway. J Int J Mol Sci 21(6):5687. https://doi.org/10.3390/ijms21165687

23. Cadoric C, Sabbir MG, Albensci BC (2016) Mechanisms of Mitochondrial Dysfunction in Alzheimer’s Disease. J Mol Neurobiol 53(9):6078–6090. https://doi.org/10.1007/s12035-015-9515-5

24. Chitranont S, Pimpanan T, Polanka P et al (2015) Apatinib induces apoptosis and autophagy by PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma. J Oncol Lett 4(20):52. https://doi.org/10.3892/ol.2016.1053

25. Shimojo Y, Kunioka K, Yoshihiro N et al (2010) Effect of rosuvastatin on atherosclerotic lesion progression and sex differences from androgen receptor level in a mouse model of amyotrophic lateral sclerosis. J Proc Natl Acad Sci USA 116:23636–23642. https://doi.org/10.1073/pnas.1901732116

26. Heiman-Pattersona TD, Deitcha JS, Blankenhorn EP et al (2005) Background and gender effects on survival in the Tg(N(SOD1-G93A)1Gur mouse model of ALS. J Journal of the Neurological Sciences 236:1–7. https://doi.org/10.1016/j.jns.2005.02.006

27. Ito H, Reika W, Jianhua Z et al (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. J Experimental Neurology 213:448–455. https://doi.org/10.1016/j.expneurol.2008.07.017

28. Tomas D, McLeod VM, Chiam MD, F, al et (2021) Dissociation of disease onset progression and sex differences from androgen receptor level in a mouse model of amyotrophic lateral sclerosis. J Scientific Reports 11:9255. https://doi.org/10.1038/s41598-021-88415-0

29. McLeod VM, Lau Chew L, Chiam Mathew DF et al (2019) Androgen receptor antagonism accelerates disease onset in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J Br J Pharmacol 176:2111–2130. https://doi.org/10.1111/bph.14657

30. Aggarwal T, Polanco MJ, Chiara S et al (2014) Androgens affect muscle, motor neuron, and survival in a mouse model of SOD1-related amyotrophic lateral sclerosis. J Neurobiology of Aging 35(8):1929–1938. https://doi.org/10.1016/j.neurobiolaging.012-2659/00104-4

31. Chechneva OV, Mayrhofer F, Daugherthy DJ et al (2014) A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury. J Cell Death Dis 5(10):e1481. https://doi.org/10.1038/cddis.2014.446

32. Hu Q, Tong Li, Lingxiao W et al (2016) Neuroprotective Effects of a Smoothened Receptor Agonist against Early Brain Injury after Experimental Subarachnoid Hemorrhage in Rats. J Front Cell Neurosci 10:306. https://doi.org/10.3389/fncel.2016.00306

33. Yuan Y, Wenxiang Z, Tao L et al (2020) Cyclopamine functions as a suppressor of benign prostatic hyperplasia by inhibiting epithelial and stromal cell proliferation via suppression of the Hedgehog signaling pathway. J Int J Mol Med 46:311–319. https://doi.org/10.3892/ijmm.2020.4569

34. Barwal J, Virender K, Yuxiang D et al (2019) Design of Hedgehog pathway inhibitors for cancer treatment. J Med Res Rev 39:1137–1204. https://doi.org/10.1007/s12892-019-00159-6

35. Jin D, Yang J, Hu J et al (2015) MCP-1 stimulates spinal microglia via PI3K/akt pathway in bone cancer pain. J Brain Res 1599:158–67. https://doi.org/10.1016/j.brainres.2014.12.043

36. Vercelli A, Mereuta OM, Garbossa D et al (2008) Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. J Neurobiol Dis 31:395–405. https://doi.org/10.1016/j.nbd.2008.05.016

37. Eric D, Morales H (2016) Spinal Cord Anatomy and Clinical Syndromes. J Semin Ultrasound CT MR 37(5):360–371. https://doi.org/10.1053/j.sult.2016.05.002

38. Zhou X, Jonathan P, Emily F et al (2016) Effect of the sonic hedgehog receptor smoothened on the survival and function of dopaminergic neurons. J Exp Neurol 283(Pt A):235–245. https://doi.org/10.1016/j.expneurol.2016.06.013

39. Li X, Yunxiao Li, Shuangli Li et al (2021) The role of Shh signalling pathway in central nervous system development and related diseases. J Cell Biochem Funct 35(3):360–371. https://doi.org/10.1007/s12020-016-0500-2

40. Kroscher WT, Therese A, Sabrina C et al (2016) Neurons diversify astrocytes in the adult brain through sonic hedgehog signalling. J Science 351(6275):849–854. https://doi.org/10.1126/science.aab3103

41. Ma X, Anna D, Fan J et al (2017) Crosstalk between Notch and Sonic hedgehog signalling in a mouse model of amyotrophic lateral sclerosis. J Neuroreport 28(3):141–148. https://doi.org/10.1097/WNR.0000000000000725

42. Chen Y, Yan Qi, Zhiqiang S (2021) The Role of Sonic Hedgehog Pathway in the Development of the Central Nervous System and...
Aging-Related Neurodegenerative Diseases. J Front Mol Biosci 8:711710. https://doi.org/10.3389/fmolb.2021.711710

Dai R, Sheng-Yin Z, Yuanpeng X et al (2011) Sonic Hedgehog Protects Cortical Neurons Against Oxidative Stress. J Neurochem Res 36:67–75. https://doi.org/10.1007/s11064-010-0264-6

Lin Y, Yiwei L, Jennifer N et al (2020) Sonic Hedgehog-Gli1 Signaling and Cellular Retinoic Acid Binding Protein I Gene Regulation in Motor Neuron Differentiation and Diseases. J Int J Mol Sci 21(11):4125. https://doi.org/10.3390/ijms21114125

Julian HR, Caro-Urrego YA, Barrera-Arenas LM et al (2021) Expression of activator proteins of SHH/GLI and PI3K/Akt/mTORC1 signaling pathways in human gliomas is associated with high grade tumors. J Experimental and Molecular Pathology 122:104673. https://doi.org/10.1016/j.yexmp.2021.104673

Jadaun KS, Sidharth M, Aarti S et al (2022) Neuroprotective Effect of Chrysophanol as a PI3K/AKT/mTOR Signaling Inhibitor in an Experimental Model of Autologous Bloodinduced Intracerebral Hemorrhage. J Current Medical Science 7:1–18. https://doi.org/10.1007/s11596-022-2496-x

Shigeru Kanda, Yasushi Mochizuki, Takashi Suematsu et al (2003) Sonic Hedgehog Induces Capillary Morphogenesis by Endothelial Cells through Phosphoinositide 3-Kinase. J Molecular basis of cell and developmental biology 10(278):8244–8249. https://doi.org/10.1074/jbc.M210635200

Harrison D, Paul M, Van Es MA et al (2018) “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. J Amyotroph Lateral Scler Frontotemporal Degener 19(7–8):495–499. https://doi.org/10.1080/21678421.2018.1457059

Elia D, Dorit M, Eti A et al (2007) Sonic hedgehog promotes proliferation and differentiation of adult muscle cells: Involvement of MAPK/ERK and PI3K/Akt pathways. J Biochimica et Biophysica Acta 1773:1438–1446. https://doi.org/10.1016/j.bbamcr.2007.06.006

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.